188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: Biodistribution, normal organ dosimetry, and toxicology

Nuclear Medicine and Biology

Volumn 25, Issue 5, 1998, Pages 441-447

  Iznaga Escobar, Normando ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Monoclonal antibodies; Radioimmunotherapy; Radiolabeling; Rhenium 188

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H 3R; MONOCLONAL ANTIBODY IOR C5; MONOCLONAL ANTIBODY IOR CEA 1; MONOCLONAL ANTIBODY IOR EGF R3; RHENIUM 188; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOISOTOPE; RHENIUM;

BLOOD TOXICITY; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; GENERATOR; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; RADIOIMMUNOTHERAPY; SHORT SURVEY; SOLID TUMOR; ANIMAL; METHODOLOGY; NEOPLASM; RADIOMETRY; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; ISOTOPE LABELING; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOMETRY; RHENIUM; TISSUE DISTRIBUTION;

EID: 0032105473     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00008-0     Document Type: Short Survey

References (58)

1. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29:1994;127-138.
2. Breitz H. B., Durham J. S., Fisher D. R., Weiden P. L., DeNardo G. L., Goodgold H., et al. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibodies. J. Nucl. Med. 36:1995;754-761.
3. Breitz H. B., Fisher D. R., Weiden P. L., Durham J. S., Ratliff B. A., Bjorn M. J., et al. Dosimetry of rhenium-186-labeled monoclonal antibodies Methods, prediction from technetium-99m-labeled antibodies and results of Phase I trials . J. Nucl. Med. 34:1993;908-917.
4. Breitz H. B., Weiden P. L., Vanderheyden J. L., Appelbaum J. W., Bjorn M. J., Fer M. F., et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy Results of Phase I trials . J. Nucl. Med. 33:1992;1099-1112.
5. 188Re radionuclide generator. NucCompact-Eur/Am. Commun. Nucl. Med. 20:1989;3-6.
6. Carrasquillo J. A., Krohn K. A., Beaumier P. L., McGuffin R. W., Brown J. P., Hellstrom K. E., et al. Diagnosis and therapy of solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat. Res. 68:1984;317-328.
7. Cohen S., Fava R. A., Sawyer S. T. Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. Proc. Natl. Acad. Sci. USA. 79:1982;6237-6241.
8. Cohen S., Ushiro N., Stoscheck C., Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 257:1982;1523-1531.
9. DeNardo S. J., DeNardo G. L., O'Grady L. F. Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using iodine-131 Lym-1 monoclonal antibody. Antibody Immunoconjug. Radiopharm. 1:1988;17-33.
10. Deutsch E., Libson K., Vanderheyden J. L., Ketring A. R., Maxon H. R. The chemistry of rhenium and technetium as related to the use of isotopes of the elements in therapeutic and diagnostic nuclear medicine. Nucl. Med. Biol. 13:1986;465-477.
11. Divgi C. R., Welt S., Kris M., Real F. X., Yeh S. D., Gralla R., et al. Phase I and imaging trial of indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst. 83:1991;97-104.
12. Earhardt G. J., Ketring A. R., Turpin T. A., Razavi M. S., Vanderheyden J. L., Fritzberg A. R. An improved tungsten-188/rhenium-188 generator for radiotherapeutic applications. J. Nucl. Med. 28:1987;656-657.
13. Earhardt G. J., Turpin T. A., Razavi M. S., Vanderheyden J. L., Su F. M. and Fritzberg A. R. (1990) A convenient W-188/Re-188 generator for therapeutic applications using low specific activity W-188. In: Technetium and Rhenium in Chemistry and Nuclear Medicine, Vol. 3, (Edited by Nicolini M. and Bandoli G.), pp. 631-634. Cortina International, Verona, Italy, and Raven Press, New York.
14. Fernández A., Pérez R., Macias A., Velandia A., Alvarez I., Ramos M., et al. Generación y caracterización primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico. Interferón y Biotecnología. 6:1989;289-299.
15. Fernández A., Spitzer E., Pérez R., Boehmer F. D., Eckert K., Zschiesche W., et al. A new monoclonal antibody for detection of EGF-receptors in Western blots and paraffin-embedded tissue sections. J. Cell. Biochem. 49:1992;157-165.
16. Gold P., Freedman S. O. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J. Exp. Med. 121:1965;439-462.
17. Goodwin R. A., Tuttle S., Bucci D. M., Jewell S. D., Martin E. W., Steplewski Z. Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A. Am. J. Clin. Pathol. 88:1987;462-467.
18. Griffiths G. L., Goldenberg D. M., Diril H., Hansen H. J. Technetium-99m, rhenium-186 and rhenium-188 direct-labeled antibodies. Cancer. 73:1994;761-768.
19. 188Re for radioimmunotherapy. Cancer Res. 51:1991;4592-4602.
20. Haunschild J., Steiner K., Faro H. P., Senekowitsch R. Pharmacokinetics of reshaped MAb 425 in three animal species. Cell. Biophys. 26:1995;167-182.
21. Hayes R. L. and Rafter J. J. (1965) Rhenium-188 as a possible diagnostic agent. In: Research Report. Medical Division, Oak Ridge Associated Universities, Tennessee. ORAU 101, pp. 74-77.
22. Limits for Intakes of Radionuclides by Workers ICRP Publication 30. 1979;Pergamon Press, New York.
23. 1990 Recommendations of the International Commission on Radiological Protection. 1991;ICRP Publication 60. Pergamon Press, New York.
24. 99mTc-Labeled anti-EGF-receptor antibody (ior egf/r3) in patients with tumor of epithelial origin I. Biodistribution and dosimetry for radioimmunotherapy . J. Nucl. Med. 39:1998;15-23.
25. Johnson V. G., Schlom J., Paterson A. J., Benett J., Magnani J. L., Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 46:1986;850-857.
26. 188Re Generator for biomedical applications. Radiochimica Acta. 65:1994;39-46.
27. Knapp F. F. Jr., Lisic E. C., Mirzadeh S., Callahan A. P. and Rice D. E. (1992) A new clinical prototype W-188/Re-188 generator to provide high levels of carrier-free Re-188 for radioimmunotherapy. In: Proceedings of the European Association of Nuclear Medicine, Vienna, Austria, pp. 183-186. Nuclear Medicine in Research and Practice. Schattauer-Verlag, Stuttgart.
28. 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res. 56:1996;3788-3795.
29. Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Furher P. Colorectal carcinoma antigens detected by hybridomas and antibodies. Somatic Cell Genet. 5:1979;957-971.
30. Larson S. M., Carrasquillo J. A., Krohn K. A., Brown J. P., McGuffin R. W., Ferens J. M., et al. Localization of 131I-labeled p97-specific F(ab) fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest. 72:1983;2101-2114.
31. Loevinger R., Budinger T. F., Watson E. E. MIRD Primer for Absorbed Dose Calculations. 1988;Society of Nuclear Medicine, New York.
32. Mateo C., Moreno E., Amour K., Lombardero J., Harris W., Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor Recovery of antagonistic activity . Immunotechnology. 3:1997;71-81.
33. Miller R. A., Oseroff A. R., Stratte P. T., Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood. 62:1983;988-995.
34. Murthy U., Basu A., Rodeck U., Herlyn M., Ross A. H., Das M. Binding of antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. 72:1987;77-89.
35. O'Donoghue J. A., Bardies M., Wheldon T. E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36:1995;1902-1909.
36. Pérez R., Pascual M. R., Macias A., Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res. Treat. 4:1984;189-193.
37. Rios M. A., Fernández A., Tormo B. R., Quintero S., Pérez I., Skoog L., et al. Heterogeneous expression of the EGF-receptor in human breast carcinoma. Anticancer Res. 12:1992;205-208.
38. Rosen S. T., Zimmer M. A., Goldman-Leikin R. Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using iodine-131-labeled monoclonal antibody. J. Clin. Oncol. 4:1987;562-573.
39. Schubiger P. A., Alberto R., Smith A. Vehicles, chelators, and radionuclides Choosing "building blocks" of an effective therapeutic radioimmunoconjugate . Bioconjug. Chem. 7:1996;165-179.
40. Shetye J., Christensson B., Rubio C., Rodensjo M., Biberfeld P., Mellstedt H. The tumor-associated antigens BR55-2, GA73-3 and GICA 19.9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res. 9:1989;395-404.
41. Simpkin D. J., Mackie T. R. EGS4 Monte Carlo determination of the beta dose kernel in water. Med. Phys. 17:1990;179-186.
42. Snelling L., Miyamoto C. T., Bender H., Brady L. W., Steplewski Z., Class R., et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma. 14:1995;111-114.
43. Snyder W. S., Ford M. R., Warmer G. G., Fisher H. L. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. Medical Internal Radiation Dose (MIRD). 1978;50-67 Society of Nuclear Medicine, New York.
44. Stabin M. G. Patient dose from diagnostic and therapeutic radiopharmaceuticals. Raabe O. G. Internal Radiation Dosimetry Health Physics Society, 1994 Summer School . 1995;375-392 Medical Physics Publishing, Madison, WI.
45. Steiner K., Haunschild J., Faro H. P., Senekowitsh R. Distribution of humanized MAb 425 (EMD 62 000) in rats and specific localization in tumor-bearing nude mice. Cell. Mol. Biol. 41:1995;179-184.
46. Takahashi H., Nakazawa S., Herlyn D. Experimental radioimmunotherapy of a xenografted human glioma using 131I-labeled monoclonal antibody to epidermal growth factor receptor. Neurol. Med. Chir. (Tokyo). 33:1993;610-615.
47. Tempest P. R., Bremmer P., Lambert M., Taylor G., Furze J. M., Carr F. J., et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology. 9:1991;266-271.
48. Tormo B. R., Gavilondo J. V., Dominguez C., Freyre M., Rodríguez T., Biberfeld P. CEA in colonic adenocarcinomas and precancerous lesions. APMIS. 97:1989;1073-1080.
49. Tormo B. R., Vázquez A. M., Chong A. Colon cancer-associated antigen expression on normal and neoplastic human tissues detected by ior C2 A novel monoclonal antibody . Biotecnol. Aplicada. 8:1991;206-215.
50. Vale D., Ashcroft T., March C., Gibson G. J., Harris A. L. Epidermal growth factor receptors in non-small-cell lung cancer. Br. J. Cancer. 55:1987;513-516.
51. 111indium-labeled CDR-grafted monoclonal antibody hCTMO1 in ovarian cancer patients. 11th International Hammersmith Conference. Lesbos, Greece.
52. Vázquez A. M., Tormo B. R., Alfonso M., Velandia A., Fernández L. E., Giscombe R., et al. Characterization of ior C5 colorectal tumor-associated antigen. Inmunología Española. 14:1995;130-132.
53. Vázquez A. M., Tormo B. R., Velandia A., Giscombe R., Ansotegui I., Jeddi-Tehroni M., et al. Characterization of colorectal antigen ior C2. Hybridoma. 11:1992;245-256.
54. Vázquez A. M., Tormo B. R., Velandia A., Gómez C. A., Alfonso M., Giscombe R., et al. Characterization of the colorectal antigen ior C2. I. The Year in Immunology. Vol. 7:1993;137-145 Karger, Basel.
55. Verhoeyen M., Milstein C., Winter G. Reshaping human antibodies Grafting an antilysozyme activity . Science. 239:1988;1534-1536.
56. Waldman T. A., White J. D., Carrasquillo J. A., Reynolds J. C., Paik C. H., Gansow O. A., et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 86:1995;4963-4975.
57. Welt S., Scott A. M., Divgi C. R., Kemedy M. E., Daghighian F., Finn R. D., et al. Radioimmunotherapy of colon cancer with monoclonal antibody A33. Tumor Targeting. 1:1995;299-300.
58. Wikstrand C. J., Hale L. P., Batra S. K., Hill M. L., Humphrey P. A., Kurpad S. N., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:1995;3140-3148.